ImmuPharma said Friday that 200 patients were recruited and dosed in its Phase III trial of Lupus drug Lupuzor. Furthermore, all 200 patients have passed the 3 months stage, with over 90% of patients (184) have passed 6 months.
ImmuPharma further said that 81 patients (40%) have passed the 9 months stage, and 46 patients (23%) have passed the full 12 months of the study. The top line results remain on track to be reported in Q1 2018, ImmuPharma said.
Commenting on the trial update, Tim McCarthy, Chairman of ImmuPharma said: “As the trial continues to progress, we are delighted to observe the continuation of our robust safety record, as Lupuzor is being administered to greater numbers of patients over a longer period of time.”
McCarthy said that further updates on this pivotal Phase III study will be given through the second half of 2017, as the trial progresses.
He also said that the company will be hosting an Investor Presentation after the AGM on Friday, which will provide the Board with an opportunity of talking through the Lupuzor trial as well providing further details on the other clinical development products in our pipeline.